Copyright Reports & Markets. All rights reserved.

Global Immune Checkpoint Inhibitors Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Immune Checkpoint Inhibitors Market Overview

      • 1.1 Product Overview and Scope of Immune Checkpoint Inhibitors
      • 1.2 Immune Checkpoint Inhibitors Segment by Type
        • 1.2.1 Global Immune Checkpoint Inhibitors Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 PD-1/PD-L1
        • 1.2.3 CTLA-4
      • 1.3 Immune Checkpoint Inhibitors Segment by Application
        • 1.3.1 Immune Checkpoint Inhibitors Consumption Comparison by Application (2014-2025)
        • 1.3.2 Lung Cancer
        • 1.3.3 Colorectal Cancer
        • 1.3.4 Breast Cancer
        • 1.3.5 Prostate Cancer
        • 1.3.6 Melanoma
        • 1.3.7 Blood Cancer
        • 1.3.8 Other
      • 1.4 Global Immune Checkpoint Inhibitors Market by Region
        • 1.4.1 Global Immune Checkpoint Inhibitors Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Immune Checkpoint Inhibitors Market Size
        • 1.5.1 Global Immune Checkpoint Inhibitors Revenue (2014-2025)
        • 1.5.2 Global Immune Checkpoint Inhibitors Production (2014-2025)

      2 Global Immune Checkpoint Inhibitors Market Competition by Manufacturers

      • 2.1 Global Immune Checkpoint Inhibitors Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Immune Checkpoint Inhibitors Production Sites, Area Served, Product Types
      • 2.5 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
        • 2.5.1 Immune Checkpoint Inhibitors Market Concentration Rate
        • 2.5.2 Immune Checkpoint Inhibitors Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Immune Checkpoint Inhibitors Production Market Share by Regions

      • 3.1 Global Immune Checkpoint Inhibitors Production Market Share by Regions
      • 3.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Immune Checkpoint Inhibitors Production
        • 3.4.1 North America Immune Checkpoint Inhibitors Production Growth Rate (2014-2019)
        • 3.4.2 North America Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Immune Checkpoint Inhibitors Production
        • 3.5.1 Europe Immune Checkpoint Inhibitors Production Growth Rate (2014-2019)
        • 3.5.2 Europe Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Immune Checkpoint Inhibitors Production (2014-2019)
        • 3.6.1 China Immune Checkpoint Inhibitors Production Growth Rate (2014-2019)
        • 3.6.2 China Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Immune Checkpoint Inhibitors Production (2014-2019)
        • 3.7.1 Japan Immune Checkpoint Inhibitors Production Growth Rate (2014-2019)
        • 3.7.2 Japan Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Immune Checkpoint Inhibitors Consumption by Regions

      • 4.1 Global Immune Checkpoint Inhibitors Consumption by Regions
      • 4.2 North America Immune Checkpoint Inhibitors Consumption (2014-2019)
      • 4.3 Europe Immune Checkpoint Inhibitors Consumption (2014-2019)
      • 4.4 China Immune Checkpoint Inhibitors Consumption (2014-2019)
      • 4.5 Japan Immune Checkpoint Inhibitors Consumption (2014-2019)

      5 Global Immune Checkpoint Inhibitors Production, Revenue, Price Trend by Type

      • 5.1 Global Immune Checkpoint Inhibitors Production Market Share by Type (2014-2019)
      • 5.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2014-2019)
      • 5.3 Global Immune Checkpoint Inhibitors Price by Type (2014-2019)
      • 5.4 Global Immune Checkpoint Inhibitors Production Growth by Type (2014-2019)

      6 Global Immune Checkpoint Inhibitors Market Analysis by Applications

      • 6.1 Global Immune Checkpoint Inhibitors Consumption Market Share by Application (2014-2019)
      • 6.2 Global Immune Checkpoint Inhibitors Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business

      • 7.1 Bristol Myer Squibb
        • 7.1.1 Bristol Myer Squibb Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.1.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 AstraZeneca
        • 7.2.1 AstraZeneca Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.2.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.2.3 AstraZeneca Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Merck & Co.
        • 7.3.1 Merck & Co. Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.3.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.3.3 Merck & Co. Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Roche / Genentech
        • 7.4.1 Roche / Genentech Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.4.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.4.3 Roche / Genentech Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Incyte Corporation
        • 7.5.1 Incyte Corporation Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.5.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.5.3 Incyte Corporation Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 NewLink Genetics
        • 7.6.1 NewLink Genetics Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.6.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.6.3 NewLink Genetics Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 ArGEN-X
        • 7.7.1 ArGEN-X Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.7.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.7.3 ArGEN-X Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Seattle Genetics
        • 7.8.1 Seattle Genetics Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.8.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.8.3 Seattle Genetics Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Pfizer
        • 7.9.1 Pfizer Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.9.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.9.3 Pfizer Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 MacroGenics
        • 7.10.1 MacroGenics Immune Checkpoint Inhibitors Production Sites and Area Served
        • 7.10.2 Immune Checkpoint Inhibitors Product Introduction, Application and Specification
        • 7.10.3 MacroGenics Immune Checkpoint Inhibitors Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Celldex Therapeutics
      • 7.12 CureTech
      • 7.13 Immutep
      • 7.14 Innate Pharma
      • 7.15 Sorrento Therapeutics
      • 7.16 GlaxoSmithKline
      • 7.17 GITR, Inc

      8 Immune Checkpoint Inhibitors Manufacturing Cost Analysis

      • 8.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
      • 8.4 Immune Checkpoint Inhibitors Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Immune Checkpoint Inhibitors Distributors List
      • 9.3 Immune Checkpoint Inhibitors Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Immune Checkpoint Inhibitors Market Forecast

      • 11.1 Global Immune Checkpoint Inhibitors Production, Revenue Forecast
        • 11.1.1 Global Immune Checkpoint Inhibitors Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Immune Checkpoint Inhibitors Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Immune Checkpoint Inhibitors Price and Trend Forecast (2019-2025)
      • 11.2 Global Immune Checkpoint Inhibitors Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Immune Checkpoint Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Immune Checkpoint Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Immune Checkpoint Inhibitors Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Immune Checkpoint Inhibitors Production, Revenue Forecast (2019-2025)
      • 11.3 Global Immune Checkpoint Inhibitors Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Immune Checkpoint Inhibitors Consumption Forecast (2019-2025)
        • 11.3.2 Europe Immune Checkpoint Inhibitors Consumption Forecast (2019-2025)
        • 11.3.3 China Immune Checkpoint Inhibitors Consumption Forecast (2019-2025)
        • 11.3.4 Japan Immune Checkpoint Inhibitors Consumption Forecast (2019-2025)
      • 11.4 Global Immune Checkpoint Inhibitors Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Immune Checkpoint Inhibitors Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.

        The global Immune Checkpoint Inhibitors market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Immune Checkpoint Inhibitors volume and value at global level, regional level and company level. From a global perspective, this report represents overall Immune Checkpoint Inhibitors market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Bristol Myer Squibb
        AstraZeneca
        Merck & Co.
        Roche / Genentech
        Incyte Corporation
        NewLink Genetics
        ArGEN-X
        Seattle Genetics
        Pfizer
        MacroGenics
        Celldex Therapeutics
        CureTech
        Immutep
        Innate Pharma
        Sorrento Therapeutics
        GlaxoSmithKline
        GITR, Inc

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        PD-1/PD-L1
        CTLA-4

        Segment by Application
        Lung Cancer
        Colorectal Cancer
        Breast Cancer
        Prostate Cancer
        Melanoma
        Blood Cancer
        Other

        Buy now